Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Yarrow BioscienceYARW -2.78%13 EV-to-EBIT is -6.78 as of Sep. 14, 2026. GuruFocus rates YARW with a GF Score™ of 13/100. Among 369 Biotechnology companies, Yarrow Bioscience ranks worse than 271002.44% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Yarrow Bioscience's Enterprise Value for the quarter that ended in Jun. 2026 was $0.00 Mil.
Yarrow Bioscience's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.96 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Yarrow Bioscience EV-to-EBIT Related Terms
Yarrow Bioscience EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Yarrow Bioscience's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Yarrow Bioscience EV-to-EBIT Chart
Yarrow Bioscience Annual Data
Trend
Dec25
EV-to-EBIT
0.00
Yarrow Bioscience Quarterly Data
Jun25
Dec25
Mar26
Jun26
EV-to-EBIT
0.00
0.00
0.00
0.00
YARW vs CGTX, RANI, VRCA: EV-to-EBIT Comparison
For the Biotechnology subindustry, Yarrow Bioscience's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Yarrow Bioscience EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Yarrow Bioscience's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Yarrow Bioscience's EV-to-EBIT falls into.
Yarrow Bioscience's current Enterprise Value is $47.18 Mil.
Yarrow Bioscience's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.96 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Yarrow Bioscience (YARW) has a EV-to-EBIT of -6.78 as of Sep. 14, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Yarrow Bioscience and its competitors. According to the industry distribution chart, Yarrow Bioscience ranks #999999 out of 369 companies in the Biotechnology industry.
Is Yarrow Bioscience's EV-to-EBIT too high?
Yarrow Bioscience's current EV-to-EBIT is -6.78. Based on the distribution chart, Yarrow Bioscience ranks #999999 out of 369 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Yarrow Bioscience has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Yarrow Bioscience's EV-to-EBIT compare to CGTX and RANI?
According to the Biotechnology industry distribution chart, Yarrow Bioscience ranks #999999 out of 369 companies for EV-to-EBIT. This places Yarrow Bioscience in the lower half of its industry. The industry median EV-to-EBIT is 14.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 14.40, based on 369 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Yarrow Bioscience and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 14.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Yarrow Bioscience's current EV-to-EBIT is -6.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Yarrow Bioscience stock overvalued right now?
Yarrow Bioscience (YARW) has a current EV-to-EBIT of -6.78. The current EV-to-EBIT is -6.78. Yarrow Bioscience's overall GF Score™ is 13/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Yarrow Bioscience (YARW), the current EV-to-EBIT is -6.78 as of Sep. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.
13GF Score
Get the complete analysis for YARW
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
YARW has been successfully added to your 
